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BACKGROUND: It is not uncommon to encounter challenges in the immunohistochemical confirmation of metastatic
breast cancer given the limited sensitivities of mammaglobin and gross cystic disease fluid protein 15 (GCDFP-15/BRST-2)
and the significant proportion of triple-negative breast carcinomas (ie, tumors that are negative for estrogen receptor
[ER], and progesterone receptor [PgR], and human epidermal growth factor 2 [HER2]). GATA binding protein 3 (GATA3)
has emerged as a potentially useful immunohistochemical adjunct during the evaluation of metastatic breast carcinomas
in cytology specimens. The objective of the current study was to examine GATA3 expression in the context of malignant
effusions secondary to both mammary and extramammary malignancies. METHODS: In total, 306 malignant effusions
(from 62 metastatic breast carcinomas and 244 extramammary malignancies) were examined using GATA3 immunohisto-
chemistry. Effusions with metastatic breast carcinoma were also examined using immunohistochemistry for additional
breast markers (ER, PgR, HER2, mammaglobin, and GCDFP-15/BRST-2). RESULTS: GATA3 immunohistochemistry high-
lighted the tumor cells in 58 of the 62 samples (93.5%) from patients with metastatic breast carcinoma, which was higher
than the observed sensitivity of immunohistochemistry for ER (63.8%), PgR (41.4%), HER2 (15.5%), mammaglobin (22.4%),
and GCDFP-15/BRST-2 (5.2%). GATA3 expression also was observed in a subset of malignant effusions secondary to
extramammary primaries, specifically, in 28 of 244 specimens (11.5%). CONCLUSIONS: GATA3 is a highly sensitive marker
for the detection of metastatic breast carcinomas in effusion specimens. However, this marker is not entirely specific for
malignancies of breast origin. Thus, GATA3 should be used in conjunction with additional immunohistochemical markers
during the cytologic evaluation of malignant effusions. Cancer (Cancer Cytopathol) 2015;123:576-81. VC 2015 American
Cancer Society.
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INTRODUCTION
GATA binding protein 3 (GATA3) is a member of the zinc finger transcription factor family that recognizes
(A/T)GATA(A/G) nucleotide sequences in target gene promoters to regulate gene transcription. GATA3 is
involved in the normal development of breast epithelium, urothelium, and a subset of lymphocytes. GATA3
has recently been reported as a sensitive marker for breast malignancies on surgical resection specimens.1–3
GATA3 and estrogen receptor (ER) are involved in a cross-regulatory loop and are frequently coexpressed in
breast carcinomas; however, several studies have demonstrated that subsets of “triple-negative” breast carcino-
mas (ie, negative for ER, and progesterone receptor [PgR], and human epidermal growth factor 2 [HER2]) also
stain positively for GATA3.2–4 This has important implications for confirming metastatic breast carcinoma in
patients who have primary and/or metastatic tumors that are negative for ER, PgR, and HER2. Furthermore,
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given the limited sensitivities of gross cystic disease fluid
protein 15 (GCDFP-15/BRST-2) and mammaglobin
immunohistochemistry for detecting breast carcinomas,5
additional immunohistochemical markers for detecting
metastatic breast carcinoma warrant investigation.
Studies examining the utility of GATA3 immuno-
histochemistry in cytologic specimens are limited in their
number and scope, and such evaluations have primarily
focused on comparing the effectiveness of GATA3 immu-
nohistochemistry to other breast immunomarkers. The
utility of GATA3 immunohistochemistry has been high-
lighted particularly in pleural effusions, as breast carci-
noma is a common source of metastasis to the pleural
fluid. In pleural effusion specimens, GATA3 is reportedly
more sensitive than both GCDFP-15/BRST-2 and mam-
maglobin as a marker for metastatic breast cancer.5,6
GATA3 is also well recognized as a sensitive marker for
urothelial carcinoma, which is helpful in patients with
metastatic carcinoma for whom differential diagnostic
considerations include metastatic urothelial carcinoma,
prostatic adenocarcinoma, and pelvic squamous cell carci-
noma.7 More recent studies in surgical resection speci-
mens reported GATA3 positivity in other malignancies,
including mesotheliomas, pancreatic adenocarcinomas,
and pulmonary adenocarcinomas.8,9
In light of the above-mentioned contributions to the
literature, we sought to expand the scope of GATA3
immunohistochemical evaluation to a large series of
malignant effusions. Specifically, we examined the sensi-
tivity of GATA3 as a marker for detecting metastatic
breast carcinomas in effusion specimens, including triple-
negative breast carcinomas. Furthermore, we examined a
variety of metastatic carcinomas of extramammary origin
to better understand the specificity of GATA3
immunohistochemistry.
MATERIALS AND METHODS
This study was approved by the Institutional Review
Board at University of Michigan. The electronic pathol-
ogy database was searched to identify consecutive patients
who had metastatic carcinoma diagnosed in pleural, peri-
cardial, and peritoneal effusion specimens at the Univer-
sity of Michigan between January 1, 2008 and December
31, 2012. Electronic medical records also were examined
to assist in determining the primary etiology of malignant
cells for each case evaluated in this study. The cytology
slides were retrieved from the archive, and the hematoxy-
lin and eosin-stained cell block sections were reviewed to
evaluate cellularity. Immunohistochemistry for GATA3
was performed on cell block material for all malignant
cases that had adequate tumor cellularity (>20 tumor
cells).
GATA3 immunohistochemistry was performed on
all specimens using formalin-fixed, paraffin-embedded
cell blocks sectioned at 5-micron thickness using the
Dako Autostainer (Dako, Carpinteria, Calif). Heat-
induced epitope retrieval was performed using the Dako
FLEX Target Retrieval Solution high-pH antigen-
retrieval buffer, pH 9.01, for 20 minutes. After quenching
of endogenous peroxidases, the anti-GATA3 mouse
monoclonal antibody (clone L50-823; 1:100 dilution;
Cell Marque, Rocklin, Calif) was applied at room temper-
ature for 30 minutes. The FLEX horseradish peroxidase
EnVision System was used for detection. Then, 3,30-dia-
minobenzidine (DAB) chromogen was applied for 10
minutes. Slides were counterstained with Harris hematox-
ylin for 5 seconds, dehydrated, and coverslipped.
Samples of metastatic breast carcinoma were also
evaluated by immunohistochemistry for ER, PgR, HER2,
GCDFP-15/BRST-2, and mammaglobin. The details are
summarized in Table 1. Anti-ER rabbit monoclonal anti-
body (clone SP1; 1:50 dilution; Cell Marque) was applied
at room temperature for 20 minutes, rabbit monoclonal
anti-PgR antibody (clone Y85; 1:40 dilution; Cell Mar-
que) was applied at room temperature for 20 minutes,
and anti-HER2 rabbit monoclonal antibody (clone SP3;
1:150 dilution; Cell Marque) was applied at room tem-
perature for 20 minutes. Mouse monoclonal antibodies
against GCDFP-15/BRST-2 (clone D6; Signet; Dedham,
Mass) and mammaglobin (clone 304-1A5; Dako) were
applied at a dilution of 1:1000 each on separate sections.
The FLEX1 rabbit or mouse EnVision System was used
for detection, and the DAB chromogen was applied for 10
minutes. Slides were counterstained with Harris hematox-
ylin for 5 seconds and were subsequently dehydrated and
coverslipped.
Immunostained slides were scored with respect to
the intensity (0, no staining; 11, weak staining; 21,
moderate staining; 31, strong staining) and extent (0, no
cells stained; 11, 1%-10% of cells stained; 21, 11%-
50% of cells stained; 31,>50% of cells stained) of tumor
cell staining. The sum of the 2 scores represented the com-
bined immunoreactivity score; a total score >2 was
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considered a positive staining result, and a combined
immunoreactivity score 2 was considered a negative
result.
RESULTS
In total, 355 specimens of malignant pleural, peritoneal,
and pericardial effusions with adequate tumor cellularity
in the cell block preparations were identified. Of these, 49
represented duplicate samples from patients, leaving a
total of 306 patient specimens for analysis in this study.
Cell block sections derived from all 306 of these speci-
mens were first assessed by GATA3 immunohistochemis-
try, including 62 specimens from breast primaries and
244 from extramammary primaries. The subtypes of the
primary breast cancers were known in 60 of the 62
patients with metastatic breast carcinoma (47 ductal, 10
lobular, and 3 mucinous carcinomas). Our observations
with regard to GATA3 expression in all of the examined
cases are summarized in Table 2.
Eighty-six of 306 specimens (28.1%) scored positive
for GATA3 expression in tumor cells, and the positive
specimens were not restricted to metastatic breast cancers
(Table 2). Fifty-eight of the 86 GATA3-positive malig-
nant effusions were derived from breast primaries; thus,
the sensitivity of GATA3 immunohistochemistry for
detecting metastatic breast carcinoma was 58 of 62 speci-
mens (93.5%). The remaining 28 GATA3-positive malig-
nant effusions were observed in metastases secondary to
extramammary primaries, including Mullerian, lung,
pancreatobiliary, urothelial, gastric, esophageal, thyroid,
and germ cell primaries (Table 2). All 3 effusions involved
by urothelial cell carcinoma were positive for GATA3.
There were 2 malignant effusions secondary to testicular
primaries—a yolk sac tumor and a choriocarcinoma—
each of which was positive for GATA3. Other primaries,
such as tumors of primary lung, Mullerian, or pancreato-
biliary origin, had a lower proportion of specimens that
were positive for GATA3 (Table 2). Two of the 28
GATA3-positive malignant effusions were derived from
carcinomas of unknown primaries in patients who had no
documented history of breast cancer. As GATA3 immu-
nohistochemistry was negative in 216 of 244 malignant
effusions secondary to extramammary primaries, the spec-
ificity of GATA3 immunohistochemistry was 88.5%.
The distribution of composite GATA3 scores, which
we determined by evaluating the extent and intensity of
TABLE 1. Summary of Antibodies Used in this
Study
Antibody Clone (Host) Dilution
Epitope
Retrieval Detection
GATA3 L50-823 (mouse) 1:100 FLEX TRSa EnVisiona
ER SP1 (rabbit) 1:50 FLEX TRS EnVision
PgR Y85 (rabbit) 1:40 FLEX TRS EnVision
HER2 SP3 (rabbit) 1:150 FLEX TRS EnVision
Mammaglobin 304-1A5 (mouse) 1:1000 FLEX TRS EnVision
GCDFP-15/
BRST-2
D6 (mouse) 1:1000 None EnVision
Abbreviations: ER, estrogen receptor; GATA3, GATA binding protein 3;
GCDFP-15/BRST-2, gross cystic disease fluid protein 15; HER2, human
epidermal growth factor receptor; PgR, progesterone receptor; TRS, target-
retrieval solution.
a The EnVision System and FLEX TRS are both from Dako (Carpinteria,
Calif).
TABLE 2. GATA Binding Protein 3 Immunohisto-
chemical Analysis for 306 Malignant Effusions








Breast 62 58 (93.5)
Ductal 47 43 (91.5)
Lobular 10 10 (100)
Mucinous 3 3 (100)
Unknown 2 2 (100)
Mullerian 109 8 (7.3)
Serous adenocarcinoma 83 7 (8.4)
Clear cell adenocarcinoma 6 0 (0)
Endometrioid adenocarcinoma 2 0 (0)
Mucinous adenocarcinoma 1 0 (0)
Mixed epithelial adenocarcinoma 3 0 (0)
Undifferentiated carcinoma 3 0 (0)
Carcinosarcoma 4 0 (0)
Endocervical adenocarcinoma 1 0 (0)
Not otherwise specifieda 6 1 (16.7)
Lung 44 6 (13.6)
Adenocarcinoma 38 5 (13.2)
Squamous cell carcinoma 2 1 (50)
Small cell carcinoma 4 0 (0)
Upper gastrointestinal tract 24 3 (12.5)
Esophageal adenocarcinoma 12 1 (8.3)
Gastric adenocarcinoma 12 2 (16.7)
Pancreatobiliary tract 26 3 (11.5)
Pancreatic adenocarcinoma 18 2 (11.1)
Cholangiocarcinoma 8 1 (12.5)
Colorectal adenocarcinoma 14 0 (0)
Unknown primary 13 2 (15.4)
Renal cell carcinoma 5 0 (0)
Urothelial carcinoma 3 3 (100)
Testicular germ cell tumor 2 2 (100)
Thyroid 2 1 (50)
Papillary thyroid carcinoma 1 0 (0)
Anaplastic carcinoma 1 1 (100)
Hepatocellular carcinoma 1 0 (0)
Penile squamous cell carcinoma 1 0 (0)
Abbreviation: GATA3, GATA binding protein 3.
a In these specimens, tumor subtyping was precluded by either the lack of
subsequent resection specimens (n 5 4), lack of residual carcinoma for
evaluation on resection specimen (n 5 1), or lack of pathology report in a
patient who had a remote history of Mullerian adenocarcinoma (n 5 1).
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GATA3 expression, according to primary site is displayed
in Table 3. Diffuse and strong GATA3 staining (compos-
ite score 5 6) was observed in the majority of GATA3-
positive malignant effusions secondary to breast primaries
(53 of 58 effusions; 91.4%) and in all urothelial primaries
(3 of 3 effusions; 100%) (Fig. 1). However, diffuse and
strong GATA3 immunoreactivity also was observed in
occasional effusions from metastatic carcinomas of extra-
mammary origin (Fig. 1). Other GATA3-positive speci-
mens in effusions from extramammary malignancies, such
as gastric, esophageal, and thyroid carcinomas, demon-
strated lower intensity and/or extent of staining for
GATA3.
After analysis by GATA3 immunohistochemistry,
58 of 62 effusion specimens from metastatic breast carci-
nomas had sufficient remaining tumor cell material in the
cell block for further evaluation of additional breast
cancer-relevant immunohistochemical markers (ER, PgR,
HER2, GCDFP-15/BRST-2, and mammaglobin). Of
the 4 effusion specimens that had insufficient cellularity
for further immunohistochemical analysis, 2 were nega-
tive for GATA3 expression, 1 had a composite GATA3
score of 4, and the remaining specimen had a composite
GATA3 score of 6. Of the 58 effusion specimens from
metastatic breast carcinomas that had sufficient cellular-
ity, 56 were positive for GATA3 (96.6%), 37 were posi-
tive for ER (63.8%), 24 were positive for PgR (41.4%), 9
were positive for HER2 (15.5%), 13 were positive for
mammaglobin (22.4%), and 3 were positive for GCDFP-
15/BRST-2 (5.2%) (Table 4). Of note, in 11 of the 58
effusions from metastatic breast carcinomas (19%),
GATA3 was the only positive marker. In the 2 GATA3-
negative effusions from metastatic breast cancer, all of the
other breast markers were also negative in the tumor cells.
TABLE 3. Immunohistochemical Scoring Distribution of GATA Binding Protein 3-Positive Cases
Combined Immunoreactivity Score: No. of Positive Cases (%)
Primary Site Total No. of Positive Cases 6 5 4 3
Breast 58 53 (91.4) 1 (1.7) 3 (5.2) 1 (1.7)
Lung 6 3 (50) 1 (16.7) 1 (16.7) 1 (16.7)
Mullerian 8 2 (25) 3 (37.5) 3 (37.5) —
Urothelial 3 3 (100) — — —
Pancreatobiliary 3 2 (66.7) — 1 (33.3) —
Gastric 2 — — 1 (50) 1 (50)
Unknown 2 — — 2 (100) —
Esophageal 1 — 1 (100) — —
Thyroid 1 — — 1 (100) —
Germ cell 2 1 (50) — 1 (50) —
Figure 1. Representative photomicrographs illustrate GATA
binding protein 3 (GATA3) expression on immunohistochem-
istry in effusion specimens from metastatic carcinomas of
breast and extramammary origin. Nuclear GATA3 expression
is observed in (A,B) 2 metastatic breast carcinomas, (C) a
lung carcinoma, (D) a Mullerian carcinoma, (E) a pancreatic
carcinoma, and (F) and a urothelial cell carcinoma (original
magnification 3 200 in A-F). Note that the nuclei of lympho-
cytes in the background can also demonstrate nuclear
GATA3 expression, and this can serve as an internal positive
control.
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A summary of GATA3, mammaglobin, and
GCDFP-15/BRST-2 expression in our cohort of 58 met-
astatic breast carcinomas categorized by the receptor pro-
file of the patients’ breast primaries is provided in Table 5.
Note that 11 of 13 triple-negative breast primaries were
positive for GATA3 (84.6%), most of which had a com-
posite immunoreactivity score of 6 (90.9%).
DISCUSSION
GATA3 has previously been cited as a useful marker for
identifying malignancies of breast and urothelial origin.
In a study by Braxton et al,10 86% of breast carcinomas
were positive for GATA3 in fine-needle aspiration and
serous effusion specimens, whereas mammaglobin and
GCDFP-15 had lower sensitivities (26% and 14%,
respectively). Their study corroborates our findings, as
93.5% of our effusions from metastatic breast carcinoma
were positive for GATA3.
It is noteworthy that previous reports of GATA3
positivity were low in cytologic specimens from patients
with triple-negative breast cancers (ie, tumors negative for
ER, and PgR, and HER2). Braxton et al reported that all
ER-positive cytology specimens with breast cancer were
positive for GATA3, but all specimens from triple-
negative breast cancers were negative for GATA3 expres-
sion.10 However, in our current study, 11 of 13 malignant
effusions (85%) involved by triple-negative breast primar-
ies were positive for GATA3. These findings agree with
more recent studies on GATA3 expression in triple-
negative breast resection specimens published by Krings
et al, who reported GATA3 expression in 44% to 66% of
primary triple-negative breast carcinomas, depending on
the subtype of GATA3 antibody used.11
Furthermore, most of the GATA3-positive, triple-
negative metastatic breast carcinoma specimens in our
study demonstrated a diffuse and intense staining pattern
for GATA3; specifically, 15 of 18 GATA3-positive, tri-
ple-negative specimens (83%) demonstrated a composite
immunoreactivity score of 6. This supports the notion
that GATA3 is a particularly useful marker for helping to
confirm a diagnosis of metastatic breast carcinoma,
including triple-negative cancers, in effusion specimens
given the lower overall sensitivities for mammaglobin and
GCDFP-15/BRST-2. It is worth noting that a review of
the composite immunoreactivity scores of the other breast
immunomarkers in our study revealed that the majority
of composite scores for GCDFP-15/BRST-2 and mam-
maglobin were 4 (Table 4). It may be helpful to keep
this in mind, particularly for cell block preparations that
have limited tumor cellularity. In such specimens, the
patchy distribution of staining for mammaglobin and
GCDFP-15/BRST-2 could further contribute to the lim-
ited sensitivity and utility of these markers in confirming
the involvement of a malignant effusion by a breast
primary.
However, caution must be exercised in patients who
have malignant effusions from unknown primaries or in
TABLE 4. Breast Cancer Immunohistochemical
Marker Analysis of 58 Malignant Effusions
Secondary to Breast Primaries
Combined Immunoreactivity





Cases (%) 6 5 4 3
GATA3 56 (96.6) 51 2 2 1
ER 37 (63.8) 29 7 1 —
PgR 24 (41.4) 7 4 8 5
HER2 9 (15.5) 5 4 — —
Mammaglobin 13 (22.4) 2 3 2 6
GCDFP-15/
BRST-2
3 (5.2) — — 2 1
Abbreviations: ER, estrogen receptor; GATA3, GATA binding protein 3;
GCDFP-15/BRST-2, gross cystic disease fluid protein 15; HER2, human
epidermal growth factor receptor; PgR, progesterone receptor.
TABLE 5. Breast Cancer Immunohistochemical
Marker Analysis Categorized by Receptor Profile of
Breast Primaries
Immunohistochemical Marker:
No. of Positive Cases (%)
Breast Primary




HER21, n 5 3
3 (100) 0 (0) 0 (0)
ER1/PgR1/
HER22, n 5 29
29 (100) 6 (20.7) 3 (10.3)
ER1/PgR2/
HER21, n 5 6
6 (100) 1 (16.7) 0 (0)
ER1/PgR2/
HER22, n 5 6
6 (100) 2 (33.3) 0 (0)
ER2/PgR2/
HER21, n 5 1
1 (100) 0 (0) 0 (0)
ER2/PgR2/
HER22, n 5 13
11 (84.6) 4 (30.8) 1 (7.7)
Abbreviations: 2, negative; 1, positive; ER, estrogen receptor; GATA3,
GATA binding protein 3; GCDFP-15/BRST-2, gross cystic disease fluid pro-
tein 15; HER2, human epidermal growth factor receptor; PgR, progesterone
receptor.
Original Article
580 Cancer Cytopathology October 2015
those who have a clinical suspicion of a second, distinct
primary. Although GATA3 positivity may be supportive
of the involvement of an effusion by a breast primary, the
findings in our study also demonstrate that a small but sig-
nificant proportion of other common etiologies of malig-
nant effusions also exhibit a range of GATA3 positivity,
including Mullerian, pancreatobiliary, lung, and upper
gastrointestinal tract primaries. Therefore, we acknowl-
edge that it is prudent to use immunohistochemistry for
GATA3 as part of a panel that includes other immunohis-
tochemical markers to help rule in or rule out these other
primary sites. For instance, immunohistochemistry for
thyroid transcription factor-1 and Napsin-A can be help-
ful in identifying metastatic lung adenocarcinoma in effu-
sions.12–14 Furthermore, paired box 8 (PAX8) can be used
to identify metastatic carcinomas of renal, thyroid, and
Mullerian origin.14–16 In this study, it is noteworthy that
there was 1 case each of a malignant effusion involved by a
testicular choriocarcinoma and yolk sac tumor, both of
which were positive for GATA3, with GATA3 composite
scores of 6 and 4, respectively. These tumors are less com-
mon and are rarely encountered in the setting of malig-
nant effusions. Nonetheless, these instances further
highlight the limitation of the utility of GATA3 in
isolation.
In summary, the high sensitivity of GATA3 immu-
nohistochemistry renders this marker a useful adjunct in
the diagnosis of malignant effusions secondary to meta-
static breast carcinoma. Nonetheless, this marker should
not be used in isolation; careful evaluation of the cyto-
morphology, clinical history, and radiologic findings, as
well as the use of a panel of markers are important for the
accurate characterization and diagnosis of malignant
effusions.
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